3SBio Inc. (HKG:1530)
Hong Kong
· Delayed Price · Currency is HKD 29.58
-0.14 (-0.47%)
At close: Dec 5, 2025
3SBio Employees
3SBio had 5,577 employees as of December 31, 2024. The number of employees increased by 166 or 3.07% compared to the previous year.
Employees
5,577
Change (1Y)
166
Growth (1Y)
3.07%
Revenue / Employee
1.59M HKD
Profits / Employee
412.33K HKD
Market Cap
70.76B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| JD Health International | 3,564 |
| Innovent Biologics | 5,659 |
| WuXi Biologics | 12,575 |
| Sino Biopharmaceutical | 24,379 |
| Akeso | 3,035 |
| Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
3SBio News
- 4 days ago - China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline - South China Morning Post
- 15 days ago - 3SBio spin-off Mandi banks on hair-loss and weight-loss drugs in Hong Kong IPO - South China Morning Post
- 5 weeks ago - Innovent's License Deal Fails To Excite investors - Benzinga
- 4 months ago - Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug - South China Morning Post
- 6 months ago - Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma - Benzinga
- 7 months ago - Pfizer Thinks Bigger With 3SBio Deal - Seeking Alpha
- 7 months ago - Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China - Investopedia
- 7 months ago - Pfizer strikes deal with China's 3SBio to license cancer drug - CNBC